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Because of its high rates of soil-to-plant 
  transfer, cadmium is a contaminant found in 
most human foodstuffs, which renders diet 
a primary source of exposure among non-
smoking, nonoccupationally exposed popu-
lations (Clemens 2006; Franz et al. 2008; 
McLaughlin et al. 2006). A safe intake limit 
of 7 µg cadmium/week/kg body weight was 
set based on the critical renal cadmium con-
centration of between 100 and 200 µg/g wet 
weight that corresponds to a urinary threshold 
limit of 5–10 µg/g creatinine [World Health 
Organization (WHO) 1989, 1993]. However, 
numerous studies have revealed adverse kidney 
effects at urinary cadmium levels < 0.5 µg/g 
creatinine (Satarug and Moore 2004). Further, 
accumulating evidence links environmental 
exposure to cadmium with increased cancer 
incidence. For example, in prospective studies 
in Japan and the United States, excess can-
cer mortality was found to be associated with 
environmental exposure to cadmium (Arisawa 
et al. 2007b; Menke et al. 2009; Nishijo 
et al. 2006). Åkesson et al. (2008) observed 
increased endometrial cancer risk in a Swedish 
cohort among participants who consumed 
> 15 µg/day of cadmium, mainly from cereals 
and vegetables. These findings suggest a very 
large health burden associated with exposure 
to cadmium at levels experienced by many 
populations worldwide.
This review provides an update on cad-
mium exposure levels and the potential adverse 
health effects they may elicit in adult popu-
lations. We focus first on key issues under-
pinning health risk assessment of low-level 
cadmium in the diet, including bioavailability 
of dietary origin, the 5% default absorption 
rate, thresholds and safe intake levels, and the 
kidney as a specific target for cadmium accu-
mulation. Second, we review epidemiologic 
studies from 2004 to 2009 that link exposure 
levels to observed effects in classic targets (kid-
ney and bone) along with newly identified 
potential target organs. We also summarize 
evidence that links cadmium with diabetes, 
diabetic nephropathy, hypertension, periph-
eral artery disease (PAD), myocardial infarc-
tion, diminished lung function, periodontal 
disease, and age-related macular degeneration 
(AMD). Evidence from prospective studies 
reveal potential causal relationships of cad-
mium exposure with life prognosis (all-cause 
mortality) and excess cancer mortality and 
suggest that cadmium is at least a comorbid-
ity factor if not a causative factor. Specifically, 
we summarize cadmium-cancer associations 
for the lung, pancreas, breast, endometrium, 
prostate, and urinary bladder. 
FAO/WHO Guidelines for  
Safe Intake
The major issue addressed in this article is 
whether the guidelines established for the safe 
intake of cadmium adequately protect indi-
viduals from increased health risk. The Food 
and Agriculture Organization/World Health 
Organization (FAO/WHO) Joint Expert 
Committee on Food Additives has defined the 
provisional tolerable weekly intake (PTWI) 
for a chemical with no intended function as 
an estimate of the amount of the chemical 
that can be ingested weekly over a lifetime 
without appreciable health risk (WHO 1989). 
The PTWI value initially set for cadmium 
was 400–500 µg/person/week (WHO 1989). 
These levels were based on a critical renal con-
centration of 100–200 µg cadmium/g wet kid-
ney cortex weight, attained after a cadmium 
intake of 140–260 µg/day for > 50 years or 
2,000 mg over a lifetime (WHO 1989). The 
PTWI model incorporates an oral absorp-
tion rate of 5% and a daily excretion rate of 
0.005% of total body burden. In 1992, the 
PTWI for cadmium was refined and subse-
quently expressed in terms of cadmium intake 
per kilogram of body weight (WHO 1993). 
This refinement also recognized that the 
model PTWI for cadmium did not include a 
safety factor and that only a very modest mar-
gin existed between the level of exposure in a 
normal diet and a level predicted to produce 
a potential effect on the kidney. Despite this 
narrow safety factor, the PTWI for cadmium 
was retained at 7 µg/kg body weight, which 
translates to 70 µg/day for a person who 
weighs 70 kg. A toxicokinetic model predicts, 
based on similar assumptions, that the renal 
cortical cadmium level of 50 µg/g wet weight 
could be attained at the cadmium intake 
of 1 µg/kg body weight/day over 50 years 
(Buchet et al. 1990). The renal cortical cad-
mium 50 µg/g wet weight corresponds to uri-
nary cadmium 2 µg/g creatinine, but kidney 
effects have been observed at urinary cadmium 
levels < 0.5 µg/g creatinine (Table 1). These 
findings argue that the current safe intake level 
does not provide sufficient health protection 
and that it should be lowered.
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Satarug et al. (2000, 2003) examined the 
PTWI model by studying cadmium accumu-
lation in kidneys and livers of environmentally 
exposed subjects. Their studies suggested that 
the safe intake level for an adult should be 
< 30 µg/day. They also showed that cadmium 
accumulation in the kidney cortex increased 
with age, reaching a plateau by 50 years of age 
(Satarug et al. 2002). An estimated dietary 
intake at 25–30 µg cadmium/day for persons 
in the 41- to 50-year-old age group would give 
rise to a total cadmium body burden of 18 mg. 
The studies indicated that the estimated intake 
of 25–30 µg/day may produce adverse kidney 
effects in about 1% of the adult population 
when variability in absorption and sensitivity 
to adverse effects among population members 
are considered in the analysis. 
Threshold-based Models 
for Safe Intake 
If the relative susceptibility of humans and ani-
mals is unknown at the time of derivation of 
PTWI, the lowest observed adverse effect level 
(LOAEL) in the most sensitive species is used, 
which adds an uncertainty factor of 100. Thus, 
the PTWI value must be substantiated by addi-
tional experimental data, and, if warranted, a 
larger uncertainty factor should be applied to 
the value. An alternative to LOAEL, the bench-
mark dose (BMD), has been used to derive 
the urinary cadmium threshold. The BMD is 
defined as the exposure level that produces a 
change in a response, known as the point of 
departure (POD). The lower 95% confidence 
interval (CI) of the BMD corresponding to a 
5% (L5) or 10% (L10) level of each index of 
an adverse effect above the background level 
may also be calculated as a threshold. Uno 
et al. (2005) estimated the BMDL10 of uri-
nary cadmium to be 0.6–1.2 µg/g creatinine 
(0.8–1.6 µg/day) in men and 1.2–3.6 µg/g 
creatinine (0.5–4.7 µg/day) in women. These 
results were based on data from 828 Japanese 
subjects (410 men, 418 women), 40–59 years 
of age, who lived in areas without apparent 
pollution. In another study, Suwazono et al. 
(2006) used data from 790 Swedish women, 
53–64 years of age, and estimated the BMD 
of urinary cadmium to be 0.6–1.1 µg/g crea-
tinine. Data from selected studies found the 
POD for early kidney and bone effects to be 
between 0.5 and 3 µg/g creatinine (Järup and 
Åkesson 2009). Using the BMD-derived uri-
nary cadmium threshold, the tolerable weekly 
intake for cadmium was 2.5 µg/kg body 
weight, which corresponds to 25 µg/day for 
a person who weighs 70 kg (European Food 
Safety Authority 2009). 
International Food Legislation
In the early 1960s, the Joint FAO/WHO 
Codex Alimentarius Commission was estab-
lished to detail international food legislation. 
In 2000, the Codex Committee for Food 
Additives and Contaminants reached an 
agreement on the principles for setting maxi-
mum levels (MLs) for cumulative food con-
taminants (Francesconi 2007). MLs were 
proposed for lead (Pb2+) and cadmium (Cd2+) 
in various food categories, including rice, soy-
bean, peanuts, and bivalve mollusks. The bio-
availability and ML of cadmium became an 
issue because certain bivalve mollusks were 
known to be naturally high in cadmium con-
tent (Francesconi 2007). A high ML for cad-
mium was based on an early study on bluff 
oysters (McKenzie et al. 1986).
Cadmium Sources and 
Bioavailability
Mollusks and crustaceans. Bivalve mollusks and 
crustaceans are filter feeders that accumulate 
metals from the aquatic environment indepen-
dent of environmental pollution, and contami-
nated waters could further increase the content 
of metals (Whyte et al. 2009). Cadmium con-
tent of some Pacific oysters was found to be 
13.5 mg/kg dry weight, whereas 2-fold higher 
cadmium content was reported for some New 
Zealand bluff oysters (Copes et al. 2008). A 
bioavailability study was conducted on 57 men 
and 19 women 20–75 years of age who were 
associated with the oyster industry (McKenzie 
et al. 1986). The subjects were divided into 
groups 1, 2, 3, and 4, according to their aver-
age weekly oyster consumption rate at < 6, 
6–24, 24 to < 72, and ≥ 72 oysters, respec-
tively. The estimated cadmium intake for sub-
jects in groups 1, 2, 3, and 4 was 34, 75, 116, 
and 250 µg/day, respectively. The estimated 
consumption for all groups, except group 1, 
exceeded the FAO/WHO safe guideline. The 
blood cadmium was higher among smokers 
than among nonsmokers. For the nonsmokers 
in group 4 (the highest consumption rate), 
the increase in blood cadmium attributable 
to oyster consumption was 1.2 µg/L. Blood 
selenium was also elevated by oyster consump-
tion, but no effect on serum zinc or copper 
levels was observed. Urinary cadmium, zinc, 
and β2-microglobulin (β2-MG) levels were 
not affected, and no relationship was found 
between cadmium intake and adverse renal 
effects, defined as glycosuria or proteinuria. In 
addition, no effect was observed on levels of 
cadmium, zinc, and copper in hair. McKenzie 
et al. (1986) concluded that interactions with 
selenium and other metals in oysters may result 
in diminished cadmium absorption. This study 
is extremely important because it has been used 
as the basis for assigning high cadmium ML 
values to allow the marketing of oysters and 
their products that contain naturally high levels 
of cadmium. It is important to note that no 
distinction is made between toxicity of natural 
versus anthropogenic cadmium. In our opin-
ion, this study had several flaws. For example, 
although dietary selenium and zinc were mea-
sured in the analysis, other determinants of 
cadmium absorption were not considered, such 
as body iron stores and the older age of the sub-
jects. Furthermore, evidence (Tables 1–5) now 
indicates that the blood cadmium 1.2 µg/L 
attributed to oyster consumption among non-
smokers in group 4 can be considered at risk, 
because blood cadmium levels of < 1 µg/L have 
been associated with adverse effects.
Recently, Copes et al. (2008) and Clark 
et al. (2007) reexamined the bioavailability of 
Table 1. Exposure levels associated with kidney and bone effects.
Study population, age, reference Exposure/outcomes
Sweden, n = 820, 53–64 years of age,  
Åkesson et al. 2005, 2006
Blood and urinary cadmium at 0.38 µg/L and 0.67 µg/g creatinine 
were associated with tubular impairment. Urinary cadmium at 
0.8 µg/g creatinine was associated with glomerular impairment.
Increased body burden of cadmium was associated with lowered 
bone mineral density, decreased serum parathyroid hormone and 
bone metabolism.
Thailand, n = 200, 16–60 years of age,  
Satarug et al. 2005
A 3-fold increase in body burden associated with 11%, 32%, and 
61% increases the probability of having high blood pressure, renal 
injury, and tubular impairment. 
Thailand, n = 224, 30–87 years of age,  
Teeyakasem et al. 2007
OR for tubular impairment was 10.6, comparing urinary cadmium 
1–5 versus > 5 µg/g creatinine.
United States, n = 4,258, ≥ 50 years of age, 
Gallagher et al. 2008
A 1.43-fold increase in osteoporosis risk, comparing urinary 
cadmium 1 versus < 0.5 µg/g creatinine
Belgium, n = 294, mean age 49.2 years of 
age, Schutte et al. 2008b
A 2-fold increase in body burden associated with increased bone 
resorption, urinary calcium loss, decreased proximal forearm bone 
density, and low serum parathyroid hormone. 
China, n = 148, 3-year observation,  
Wu et al. 2008
Progressive tubular and glomerular impairment was observed 
among those with urinary cadmium > 10 µg/g creatinine.
United Kingdom, n = 160, 18–86 years of 
age, Thomas et al. 2009
Risk for early renal effectsa was increased by 2.6-fold and 3.6-fold, 
comparing urinary cadmium 0.3 versus < 0.5 versus ≥ 0.5 µg/g 
creatinine.
United States, n = 14,778, > 20 years of 
age, Navas-Acien et al. 2009 
Risk for albuminuria was 2.34 and risk for lowered glomerular filtra-
tion rate was 1.98, comparing those in the highest versus lowest 
quartiles of blood cadmium and lead.
OR, odds ratio.
aEarly renal injury was defined as urinary NAG > 2 IU/g creatinine.Satarug et al.
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cadmium in oysters and showed the effects of 
consuming oysters on cadmium body burden 
and serum elemental composition (selenium, 
zinc, copper). Copes et al. (2008) considered 
the potential confounding effects of age and 
cigarette smoking and restricted their study 
to nonsmokers (33 men, 28 women) between 
33 and 64 years of age (mean age, 47.3 years). 
They estimated that the cadmium intake 
from oysters was 174 µg/week (24.8 µg/day). 
Significant increases in blood and urinary cad-
mium levels were found to be associated with 
the duration of oyster farming of at least 12 
years during which time the on average con-
sumption rate was 18 oysters/week (87 g/week). 
For the study participants, the average (range) 
blood cadmium was 0.83 (0.34–2.27) µg/L, 
and the average urinary cadmium (range) was 
0.76 (0.16–4.04) µg/g creatinine. The mean 
urinary cadmium 0.76 µg/g creatinine was 
2.5-fold greater than that of U.S. female non-
smokers, mean age 55 years, as defined in the 
study by McElroy et al. (2007). Cadmium in 
a shellfish diet was shown to be bioavailable in 
the study by Vahter et al. (1996) who found 
cadmium intake to be 11 µg/day for women in 
the mixed-diet group and 28 µg/day for those 
in the high-shellfish diet group. No differences 
in blood or urine cadmium levels were observed 
between the two groups. However, an increase 
in blood cadmium of 63% and an increase in 
urinary cadmium of 24% were found among 
those consuming the high-shellfish diet who 
had plasma ferritin levels < 20 µg/L when com-
pared with those who consumed mixed diets 
and had the same low body iron stores. Thus, 
these studies strongly suggest that cadmium 
in oysters and shellfish is bioavailable and that 
long-term oyster consumption does result in a 
higher body burden of cadmium.
Oilseeds. Sunflower seeds, peanuts, 
flaxseed, and linseed accumulate cadmium 
from the soil in a manner similar to that of 
tobacco. Cadmium levels in sunflower ker-
nels range from 0.2 to 2.5 mg/kg. Reeves and 
Vanderpool (1997) conducted a study on 
75 male and female nonsmokers who were 
30–70 years of age. Using a self-reported food-
frequency survey, those subjects who reported 
consuming > 28 g of sunflower kernels per 
week were considered high consumers. An 
analysis of a duplicate diet among controls 
showed that on average cadmium intake was 
36 µg/day, but intake was not determined for 
any of the high consumers. Blood and urinary 
cadmium levels were used as indicators of cad-
mium body burden. The expected increased 
cadmium body burden could not be demon-
strated, probably because of the limited num-
ber of subjects and the short time frame of the 
study. However, evidence for kidney effects, 
reflected by urinary β2-MG and N-acetyl-β-
d-glucosaminidase (NAG) levels, was found 
among high consumers of sunflower seeds. 
These data may indicate that cadmium in 
sunflower kernels possess a high nephrotoxic 
potential. Alternatively, they may indicate 
increased sensitivity to cadmium renal toxicity 
in the high sunflower-kernel consumers.
Offal. High cadmium levels (7–76 mg/kg 
wet weight) were found in the offal of dugongs 
and turtles that constituted the diet in the 
Torres Strait (Australia). Haswell-Elkins et al. 
(2007a) examined cadmium body burden in 
relation to offal consumption among residents 
in two communities with varying dugong and 
turtle catch statistics. Of the 182 subjects, 
12% had urinary cadmium > 2 µg/g creati-
nine, and the group mean urinary cadmium 
was 0.83 µg/g creatinine. Age accounted for 
46% of total variation in urinary cadmium 
levels, and sex (female) and current smok-
ers accounted for 7% and 4.7% of variation, 
respectively. In a second study, Haswell-Elkins 
et al. (2007b) found high cadmium body bur-
den associated with higher consumption of 
turtle liver and kidney and with locally gath-
ered clams, peanuts, and coconuts. The sum 
of these foods, heavy smoking, age, and waist 
circumference accounted for 40% of variation 
in cadmium body burden (p < 0.05). Thus, 
this study showed that local offal consumption 
is linked with high cadmium body burden. 
Cadmium levels are higher in liver and 
kidney than in muscle and older animals 
(Prankel et al. 2005). Average cadmium in the 
liver and kidney of wild moose was 2.11 and 
20.2 µg/g wet weight, respectively (Arnold 
et al. 2006). Notably, chronic, low-dose expo-
sure situations produce 10- to 20-fold higher 
cadmium in kidney than liver. It is worth not-
ing that no difference was observed in bioavail-
ability of ionic cadmium versus protein bound 
cadmium. In the human gastrointestinal tract, 
Table 2. Exposure levels associated with diabetes and hypertension. 
Study population, age, reference Exposure/outcomes
United States, n = 8,722, ≥ 40 years of age; 
Schwartz et al. 2003
OR for abnormal fasting glucose was 1.48, 2.05, comparing urinary 
cadmium < 1 versus 1.00–1.99 versus ≥ 2 µg/g creatinine, 
respectively. OR for diabetes was 1.24, 1.45, comparing urinary 
cadmium < 1 versus 1.00–1.99 versus ≥ 2 µg/g creatinine, 
respectively.
China, n = 229, 44–87 years of age with 
type 2 diabetes, mean diabetic duration 
8.6 years; Chen et al. 2006
OR for tubular impairment was 3.34, comparing urinary cadmium 
< 1 versus ≥ 1 µg/g creatinine; it was increased to 5.56, 
comparing those with low versus high levels of circulating 
metallothionein antibody. 
Pakistan, n = 238 men, 31–60 years of age 
with type 2 diabetes, diabetic duration 16 
years, 196 controls; Afridi et al. 2008
Subjects with diabetes had higher levels of cadmium in hair, blood, 
and urine than did controls. Mean blood (urinary) cadmium was 
4.2 (3.2) µg/L among nonsmoker controls and 5.7 (4.6) µg/L among 
nonsmoker cases. 
Torres Strait, Australia, n = 182;  
Haswell-Elkins et al. 2008
A dose response between urinary cadmium and glomerular 
impairment was observed among subjects with type 2 diabetes 
after adjusting for confounders. 
Korea, n = 1,902; Eum et al. 2008  OR for hypertension was 1.51, comparing blood cadmium in the 
lowest versus the highest tertile. 
United States, n = 10,991 ≥ 20 years of 
age; Tellez-Plaza et al. 2008
Mean difference in systolic blood pressure between blood cadmium 
in the 90th versus 10th percentile was 1.36 mmHg (95% CI, –0.28 
to 3.00), whereas the mean difference in diastolic blood pressure 
was 1.68 mmHg (95% CI, 0.57 to 2.78).
OR, odds ratio.
Table 3. Exposure levels associated with effects on newly identified targets.
Targets/study population, reference Exposure/outcomes
Blood vessels: United States, n = 2,125,  
Navas-Acien et al. 2004; 
n = 790, Navas-Acien et al. 2005
OR for PAD of 1.07, 1.30, and 2.82, when comparing blood cadmium 
quartiles 2, 3, and 4 versus the lowest (p for trend = 0.01).
OR for PAD of 3.05, when comparing urinary cadmium of the 75th 
versus the 25th percentile. 
Blood vessels: Belgium, n = 557;  
Schutte et al. 2008a
Increased body burden associated with lower aortic pulse wave 
velocity, lower pulse pressure, and higher femoral distensibility. 
Heart: United States, n = 4,912;  
Everett and Frithsen 2008
OR for female myocardial infarction was 1.8, comparing urinary 
cadmium ≥ 0.88 versus < 0.43 µg/g creatinine. 
Lung: United States, n = 96;  
Lampe et al. 2008 
Increased body burden was associated with reduced lung function 
among smokers. 
Periodontal tissues: United States,  
n = 11,412; Arora et al. 2009
A 3-fold increase in urinary cadmium associated with 54% higher 
prevalence odds for periodontal disease. 
Eye: United States, n = 53 cases,  
53 controls; Erie et al. 2007
Higher urinary cadmium associated with AMD in smokers. 
Mammary gland: Austria, n = 124; 
Gundacker et al. 2007 
Intake of supplement was associated with lowered breast milk 
cadmium only in nonsmokers. 
Mammary gland: Bangladesh, n = 123; 
Kippler et al. 2008
Manganese, iron, and calcium in breast milk correlated with 
cadmium content. 
OR, odds ratio.Cadmium in food and human health
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the protein bound to cadmium is digested 
and ionic cadmium released; thus speciation 
of cadmium in food would not be a basis for 
assigning high cadmium MLs for marketing 
purposes (Francesconi 2007). There has been 
no indication of decreases in food cadmium 
content over the past decade or any drastic 
change in dietary habits. In a British study, 
Lyon et al. (1999) showed that human kidney 
cadmium levels were static over a period of 16 
years (1978–1993) but were higher than those 
found in studies conducted in the early 20th 
century. The distribution of kidney cadmium 
concentrations was skewed, with about 3.9% 
of the 2,700 samples > 50 µg/g kidney cortex 
wet weight, although the population mean was 
only 19 µg/g wet weight (Lyon et al. 1999).
Cadmium Exposure and  
Effects Observed
Kidney and bone: chronic high-dose effects. 
Long-term exposure to high-dose cadmium 
causes Itai-itai disease. This disease affects 
mainly women and is characterized by severely 
impaired tubular and glomerular function and 
generalized osteomalacia and osteoporosis that 
result in multiple bone fractures (Inaba et al. 
2005). An estimate of cadmium intake, based 
on historic rice cadmium content, in the 
Itai-itai disease endemic area during the 1960s 
was 600 µg/day, and the threshold lifetime 
intake was estimated to be between 1,580 and 
2,000 mg of cadmium (Kobayashi et al. 2002, 
2006). In two reports, investigators showed 
that the lifetime threshold for early onset of 
the Itai-itai disease was less than a 3-fold dif-
ference from the intake observed in areas with 
no apparent pollution (Inaba et al. 2005; Uno 
et al. 2005). This may reflect a small safety 
margin between population intake levels and 
the levels that produce overt effects.
Kidney and bone: chronic low-dose effects. 
Long-term exposure to low-dose cadmium has 
been linked to tubular impairment with a loss 
of reabsorptive capacity for nutrients, vitamins, 
and minerals. These losses include zinc and 
copper bound to the metal binding protein 
metallothionein (MT), glucose, amino acids, 
phosphate, calcium, β2-MG, and retinol-bind-
ing protein (RBP) [International Programme 
on Chemical Safety (IPCS) 1992]. The abnor-
mal urinary excretion of low-molecular-weight 
proteins, calcium, amino acid, phosphate and 
glucose observed in cadmium-exposed indi-
viduals share some similarities with Fanconi’s 
syndrome, a genetic disorder of renal tubular 
transport. Urinary markers for cadmium effects 
are cadmium itself, low-molecular-weight sub-
stances, and the enzymes of renal tubular ori-
gin, such as NAG (Teeyakasem et al. 2007). In 
general, the urinary cadmium level reflects the 
body burden over long-term exposure before 
the development of kidney damage, and blood 
cadmium is considered an indicator of recent 
exposure (IPCS 1992). However, for persons 
> 60 years of age, blood cadmium is consid-
ered a better estimate of body burden than is 
  urinary cadmium.
Kidney and bone: the Cadmibel project. 
The Cadmibel study was one of the earliest 
investigations to examine the effects of low-
dose exposure among 2,327 Belgian subjects 
between 1985 and 1989 (Buchet et al. 1990). 
The results demonstrated that there was a 10% 
probability of having tubular impairment when 
urinary cadmium levels exceeded 2–4 µg/day. 
The result was derived from a logistic regres-
sion of urinary cadmium and various mark-
ers, including urinary calcium, amino acids, 
NAG, RBP, and β2-MG. These markers 
demonstrated different thresholds for urinary 
cadmium levels. More than 10% of values for 
each marker were abnormal when urinary cad-
mium (micrograms per day) exceeded 1.92 for 
calcium, 2.74 for NAG, 2.87 for RBP, 3.05 
for β2-MG, and 4.29 for amino acids. The 
findings showed that urinary calcium excre-
tion increased by 10 mg/day for every 2-fold 
increment in urinary cadmium excretion. An 
increased susceptibility to cadmium among 
subjects with diabetes was noted. 
Kidney and bone: current exposure   levels. 
Compelling evidence has linked tubu-
lar impairment with urinary calcium loss, 
rapid bone demineralization, and osteopo-
rosis (Table 1). For example, Åkesson et al. 
(2005) showed that tubular impairment 
among women 53–64 years of age was associ-
ated with blood and urinary cadmium lev-
els of 0.38 µg/L and 0.67 µg/g creatinine, 
respectively. Glomerular impairment was 
associated with urinary cadmium of 0.8 µg/g 
creatinine. In another study, Åkesson et al. 
(2006) used the same population and showed 
the body burden associated with decreased 
bone mineral density They also showed that 
participants with diabetes had increased sus-
ceptibility to the renal effects of cadmium 
and that menopausal women were more sus-
ceptible to cadmium-induced bone effects 
than were nonmenopausal women. The risk 
for osteoporosis among women ≥ 50 years of 
age increased by 43% when urinary cadmium 
levels were compared between groups with 
Table 4. Exposure levels associated with mortality and cancer mortality.
Study population, reference Exposure/outcomes
Kakehashi (Japan) cohort, n = 3,178, 
15-year observation; Nakagawa et al. 
2006; Nishijo et al. 2006
Hazard ratio for cancer mortality was 2.5 among women with 
permanent tubular impairment.a
Hazard ratio for all-cause mortality was 2.09 among women with 
urinary cadmium ≥ 3 µg/g creatinine.
Nagasaki (Japan) cohort I, n = 275,  
23-year observation; Arisawa et al. 2007a
OR for cancer mortality was 2.58 among those with tubular 
impairment.a OR for all-cause mortality was 1.41 among those 
with permanent tubular impairment.a 
Nagasaki cohort II, n = 329,  
13-year observation; Arisawa et al. 2007b
No effects of body burden of cadmium on mortality were observed.
Belgian cohort, n = 956, 20.3-year median 
observation; Nawrot et al. 2008
Mortality increased by 20% and 44% in low- and high-exposure 
areas, respectively, among those with a 2-fold increase in  
body burden.
Mortality increased by 25% and 33% in low- and high-exposure 
areas, respectively, among those with a 2-fold increase in  
blood cadmium.
U.S. cohort, n = 13,958, Menke et al. 2009  Male hazard ratio was 1.7 for all-cause mortality and 4.3 for cancer 
mortality, comparing urinary cadmium < 0.21 versus > 0.48 µg/g 
creatinine.
OR, odds ratio.
aIrreversible tubular impairment was defined as urinary β2-MG ≥ 1,000 µg/g creatinine.
Table 5. Exposure levels associated with cancer.
Cancer/study population, reference Exposure/risk estimate
Lung, Belgium, n = 994, 15-year 
observation; Nawrot et al. 2006
Hazard ratios of 1.7, 2.6, and 1.6 were attributed to a 2-fold 
increase in body burden, living in high-exposure area, and  
a 2-fold increase in soil cadmium, respectively.
Pancreas, Egypt, n = 31 cases, 52 controls; 
Kriegel et al. 2006
ORs of 1.12 and 3.25 were attributed to elevated serum cadmium 
and farming occupation, respectively. 
Breast, United States, n = 246 cases, 254 
controls; McElroy et al. 2006
OR of 2.3 when comparing urinary cadmium < 0.26 versus  
≥ 0.58 µg/g creatinine
Endometrium, Sweden, n = 30,210, 16-year 
observation; Åkesson et al. 2008
OR of 2.9 was attributed to cadmium intake > 15 µg/day. 
Prostate, China; n = 297, Zeng et al. 2004 Dose response between body burden and abnormal serum  
PSA levels
Prostate, Italy, n = 45 cases, 58 controls; 
Vinceti et al. 2007 
OR of 4.7 when comparing nail cadmium content in the lowest 
versus the highest quartile
Prostate, United States, n = 422; 
Wijngaarden et al. 2008
An increase of urinary cadmium to 1 µg/g creatinine associated 
with a 35% increase in serum PSA
Urinary bladder, Belgium, n = 172 cases, 
395 controls; Kellen et al. 2007
OR of 5.7 when comparing blood cadmium in the lowest versus  
the highest tertile
Abbreviations: OR, odds ratio; PSA, prostate-specific antigen.Satarug et al.
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urinary cadmium < 0.5 and > 1.0 µg/g crea-
tinine (Gallagher et al. 2008). In a prospec-
tive study of Flemish women, Schutte et al. 
(2008b) found bone effects among those with 
a 2-fold increase in body cadmium burden, 
but no tubular effects were documented in 
the population. 
In Thailand, Satarug et al. (2005) found 
that tubular impairment and renal injury were 
associated with increased risk of high blood 
pressure among subjects 16–60 years of age 
who had mean urinary cadmium of 0.39 µg/L 
and mean serum cadmium of 0.47 µg/L. They 
demonstrated that a 3-fold increase in uri-
nary cadmium (0.39 to 1.12 µg/L) was asso-
ciated with an 11%, 32% and 61% increase 
in the probability of having high blood pres-
sure, renal injury, and tubular impairment, 
respectively. The probability of having high 
blood pressure was increased by 20% among 
those with evidence of renal injury. The odds 
of tubular impairment were found to be 
10.6 times higher when comparisons were 
made between urinary cadmium levels of 
1–5 versus > 5 µg/g creatinine (Teeyakasem 
et al. 2007). Thomas et al. (2009) reported a 
dose–response relationship between urinary 
cadmium and early renal injury, whereas Wu 
et al. (2008) found progressive tubular and 
glomerular impairment among those with uri-
nary cadmium > 10 µg/g creatinine. In a study 
of 14,778 U.S. adults > 20 years of age with 
mean blood cadmium and lead of 0.41 µg/L 
and 1.58 µg/L, respectively, Navas-Acien et al. 
(2009) found that the risk for albuminuria was 
2.34; it was 1.98 for lowered glomerular filtra-
tion rate among those in the highest quartiles 
of blood cadmium and lead than among those 
in the lowest. These findings suggest that envi-
ronmental exposure to cadmium and lead may 
constitute the risk factors for chronic kidney 
disease in the United States. 
Diabetes. Schwartz et al. (2003) dem-
onstrated a dose response between urinary 
cadmium level and an increased risk of pre-
diabetes and diabetes. The risk estimates for 
abnormal fasting glucose and diabetes were 
1.48 and 1.24 when comparisons were made 
for urinary cadmium levels of < 1 with those 
between 1.00 and 1.99 µg/g creatinine. These 
values increased to 2.05 and 1.45 when they 
compared urinary cadmium < 1 µg/g with 
≥ 2 µg/g creatinine, respectively. As noted by 
Edwards and Prozialeck (2009), the incidence 
of diabetes is rising globally and has reached 
epidemic levels in some nations. Thus, the 
potential role played by low-dose cadmium 
in prediabetes and diabetes warrants further 
research. In a study involving Chinese subjects 
between 44 and 78 years of age (mean, 66 
years) with type 2 diabetes, Chen et al. (2006) 
found tubular impairment among those who 
had had diabetes for 8.6 years. They also 
noted that the risk for tubular impairment was 
increased by 3.34 when they compared urinary 
cadmium of < 1 versus ≥ 1 µg/g creatinine and 
by 5.56 when they compared low versus high 
levels of circulating MT antibody. These data 
suggested increased susceptibility to cadmium 
tubular effects among diabetic subjects with 
high MT antibody in plasma. The authors 
considered that mean urinary cadmium 0.38 
µg/g creatinine and mean blood cadmium 
0.61 µg/L were below threshold for glomeru-
lar effects. Afridi et al. (2008) reported higher 
blood and urinary cadmium among Pakistani 
men 31–60 years of age who had had type 2 
diabetes, on average, for 16 years. 
Diabetic nephropathy. A dose–response 
relationship has been observed between uri-
nary cadmium and albuminuria among Torres 
Strait subjects with type 2 diabetes (Haswell-
Elkins et al. 2008). For persons with diabetes, 
the geometric mean for urinary cadmium with 
albuminuria was 61% higher than for those 
without albuminuria. For those without albu-
minuria, the average urinary cadmium level 
was 0.74 µg/g creatinine. The higher urinary 
cadmium levels among diabetic subjects could 
be the result of extensive kidney damage that 
leads to the release of cadmium in the kidney 
into the urine. One way to interpret these data 
is to suggest that the threshold urinary cad-
mium for people with diabetes should be no 
greater than 0.74 µg/g creatinine to prevent or 
delay the onset of renal complications. Such 
an interpretation considers albuminuria to be 
a predictor of glomerular impairment, end-
stage renal failure, and adverse cardiovascular 
outcomes. A similar threshold was suggested in 
another study that found glomerular impair-
ment associated with the urinary cadmium 
0.8 µg/g creatinine (Åkesson et al. 2005).
Hypertension. Eum et al. (2008) observed 
a dose–response relationship between urinary 
cadmium and hypertension. Of the Korean 
subjects in their study, 26.2% were hyper-
tensive. For this population, the mean blood 
cadmium was 1.67µg/L, and the risk estimate 
for hypertension was 1.51 when blood cad-
mium levels in the lowest tertile were com-
pared with those in the highest. An association 
was also found between blood cadmium and 
blood pressure levels in a U.S. sample popu-
lation, where the mean blood cadmium was 
3.98-fold lower than the mean level found in 
the Korean study (Tellez-Plaza et al. 2008). 
The strength of the cadmium blood pressure 
association was greatest among nonsmokers, 
intermediate among former smokers, and small 
or absent among current smokers. These find-
ings support “pressor” effects, which have been 
shown to be characteristic of chronic exposure 
to low-dose cadmium (Satarug et al. 2005).
Blood vessels and the heart. A set of studies 
has found evidence linking an increased risk of 
PAD with low-dose cadmium exposure (Navas-
Acien et al. 2004, 2005). The risk for PAD was 
1.07, 1.30, and 2.82 when blood cadmium 
quartiles 2, 3, and 4 were compared with the 
lowest quartile (p for trend = 0.01). Evidence 
that cadmium might be a key contributor to 
the high PAD risk was the finding that the 
risk of PAD for current smokers was 4.13-fold 
higher than for those who never smoked; for 
never smokers, the risk of PAD diminished 
to 1.84 after controlling for cadmium. In this 
study, subjects with PAD had 36% higher uri-
nary cadmium than did those without disease 
where average urinary cadmium of the sample 
group was 0.36 µg/L and where the 25th and 
90th percentile urinary cadmium level was 
0.19 and 1.16 µg/L, respectively. Furthermore, 
the PAD risk was found to be 3.05 when the 
75th percentile urinary cadmium was com-
pared with that of the 25th percentile (Navas-
Acien et al. 2005). It has also been shown that 
increased cadmium body burden is associated 
with lower aortic pulse wave velocity, lower 
pulse pressure, and higher femoral distensibility 
among subjects from low and high cadmium 
exposure areas (Schutte et al. 2008b). Everett 
and Frithsen (2008) found the risk of myocar-
dial infarction among female subjects to be 1.8 
when urinary cadmium > 0.88 µg/g creatinine 
was compared with < 0.43 µg/g creatinine. The 
risk remained when the analysis was restricted 
to nonsmokers.
Lung. Lampe et al. (2008) examined the 
potential effects of exposure to cadmium on 
lung function using a sample group of 96 men 
who underwent one to three lung function 
tests between 1994 and 2002. They found a 
reduction in forced expiratory volume in 1 sec 
(a reflection of lung function) associated with 
increased urinary cadmium among those who 
smoked. These data suggest that lung disease 
among smokers may be mediated in part by 
cadmium, because urinary cadmium is also a 
marker of cumulative smoking, an established 
risk factor in lung disease.
Periodontal tissues. A 3-fold increase in uri-
nary cadmium (0.18 versus 0.63 µg/g creati-
nine) has been reported to be associated with a 
54% higher prevalence odds ratio (OR) for peri-
odontal disease. For example, Arora et al. (2009) 
found that among a sample of adults, 15.4% 
had periodontal disease. The age-adjusted mean 
urinary cadmium for subjects with periodontal 
disease was 0.50 µg/g creatinine and 0.30 µg/g 
creatinine for unaffected individuals. 
Ocular tissues. Higher urinary cadmium 
was found to be associated with AMD among 
smokers (Erie et al. (2007). The median uri-
nary cadmium level of current and former 
smokers with AMD was 1.18 µg/g creatinine. 
This level was 1.97-, 2.03-, and 2.07-fold 
higher than that of smokers without AMD, 
nonsmokers with AMD, and nonsmokers 
without disease, respectively. Increased retinal 
cadmium content has also been found in male 
subjects with AMD (Wills et al. 2008, 2009). Cadmium in food and human health
Environmental Health Perspectives  •  v o l u m e  118 | n u m b e r 2 | February 2010  187
Mammary gland. Gundacker et al. (2007) 
showed that breast milk samples of Austrian 
subjects contained, on average, a cadmium 
content of 0.086 µg/L and that breast milk 
cadmium content was lower among nonsmok-
ers who took vitamins and mineral supple-
ments (p < 0.05). In a study by Kippler et al. 
(2008), the median cadmium level in breast 
milk from Bangladeshi subjects was 1.6-fold 
higher than was the level from Austrian sub-
jects. The investigators observed a correlation 
between cadmium and the elemental com-
position of milk, including manganese, iron, 
and calcium levels. Their findings suggest a 
potential influence of cadmium on mammary 
gland metal transport and secretion. 
Cadmium and cancer. Cadmium is clas-
sified as a cancer-causing agent in humans 
based on an elevated incidence of lung cancer 
and mortality data derived from the occupa-
tional groups with evidence of elevated expo-
sure to cadmium. Occupational exposures 
have historically been through inhalation 
[International Agency for Research on Cancer 
(IARC) 1993]. A consequence of this initial 
association of inhaled cadmium with cancer 
in occupationally exposed workers is that a 
carcinogenic risk from cadmium of dietary 
origin has long been ignored by regulatory 
agencies. However, literature to support a 
role for dietary cadmium that shows exposure 
levels associated with increased mortality risk 
and cancer mortality does exist as summarized 
in Table 4. In the Kakehashi cohort, a 2.5-
fold increase in cancer mortality was observed 
among women with permanent tubular 
impairment (Nishijo et al. 2006). This study 
also noted increased mortality from nephritis, 
nephrosis, heart failure, and brain infarction 
among both men and women with severely 
impaired tubular function. Baseline median 
urinary cadmium values for men and women 
in the Kakehashi cohort were 7.0 and 12.1 
µg/g creatinine, respectively. This cohort was 
also used to establish a dose response show-
ing the lowest urinary cadmium of 3 µg/g 
creatinine associated with excess female mor-
tality risk (Nakagawa et al. 2006). Similarly, 
Arisawa et al. (2007a) observed an increased 
mortality rate among subjects with permanent 
tubular impairment in the Nagasaki cohort I. 
They also observed a 2.58-fold concurrent 
increased risk of cancer mortality among 
those with tubular impairment. The determi-
nants of increased mortality were renal injury, 
tubular impairment, and renal insufficiency. 
These effects of cadmium were absent in the 
Nagasaki cohort II study, most likely because 
of the selective loss of advanced cases and 
the reduction in exposure after soil restora-
tion that was undertaken between 1980 and 
1983 (Arisawa et al. 2007b). Of note, the 
cadmium exposure levels in the Kakehashi 
and the Nagasaki cohorts were close to the 
levels experienced by people in a cadmium 
pollution area in Thailand (Teeyakasem et al. 
2007). 
In contrast to the above studies, the cad-
mium exposure in a Belgian cohort and in a 
U.S. cohort was below the level that would 
cause renal injury and yet increased mortality 
was observed in these studies. In the Belgian 
cohort, Nawrot et al. (2008) observed a 20% 
increase in mortality in the low-exposure area. 
This percentage was increased by 44% in the 
high-exposure area. Further, mortality risks 
were increased by 25% and 33% among those 
with a 2-fold increase in blood cadmium who 
resided in low- and high-exposure areas, respec-
tively. Menke et al. (2009) observed in the U.S. 
cohort, an increase in cancer mortality by 4.29-
fold among men with urinary cadmium lev-
els < 0.21 versus > 0.48 µg/g creatinine. They 
also observed a 1.68-fold increase in all-cause 
mortality among men after adjusting for cad-
mium exposure from cigarette smoking. Mean 
urinary cadmium for men in the U.S. cohort 
was 0.28 µg/g creatinine, which was 1.43-fold 
lower than that for women. 
Cadmium as a multitissue carcinogen. A 
substantial number of recent reports have noted 
a link between cadmium and cancer in non-
occupationally exposed populations (Table 5). 
In the 15-year Belgian cohort, Nawrot et al. 
(2006) observed a 1.7-, 4.2- and 1.57-fold 
increase in lung cancer risk among those with 
a 2-fold increase in cadmium body burden, 
those living in a high exposure area, and those 
with a 2-fold increase in soil-cadmium content, 
respectively. Serum cadmium and a farming 
occupation have been associated with pancrea-
tic cancer with the risk attributed to increased 
serum cadmium of 1.12 µg/L and of 3.25 µg/L 
for farming occupation (Kriegel et al. 2006). A 
dose response between breast cancer risk and 
cadmium exposure could be seen when indi-
viduals with urinary cadmium of ≤ 0.26 were 
compared with those with ≥ 0.58 µg/g crea-
tinine, suggesting a 2.29-fold increase in risk 
(McElroy et al. 2006). In a prospective study, 
Åkesson et al. (2008) found a 2.9-fold increase 
in endometrial cancer risk among women with 
cadmium intake greater than an average value 
of 15 µg/day; 80% of cadmium intake was 
derived from cereals and vegetables. Several 
studies have examined prostate disease. A 
dose–response relationship was shown between 
urinary cadmium and abnormal serum lev-
els of prostate specific antigen (PSA) (Zeng 
et al. 2004). It has also been shown that an 
increase in urinary cadmium to 1 µg/g creati-
nine is associated with a 35% increase in serum 
PSA level among men whose zinc intakes were 
< 12.7 mg/day (van Wijngaarden et al. 2008). 
Safe and adequate zinc intake for an adult is 
15 mg/day (Slikker et al. 2004). A 4.7-fold 
increase in prostate cancer risk was found 
among subjects where toenail cadmium was 
compared between individuals with < 0.007 
and among those with > 0.03 µg cadmium/g 
toenail (Vinceti et al. 2007). In a study of blad-
der cancer, Kellen et al. (2007) demonstrated a 
5.7-fold increase in risk between subjects with 
blood cadmium at the lowest tertile versus the 
highest. The risk estimate was corrected for sex, 
age, smoking habits, and workplace exposure. 
Mean blood cadmium for bladder cancer cases 
was 1.1 µg/L and this level was 1.6-fold higher 
than that of the controls. 
Cadmium Body Burden
Sex and tissue differential cadmium accu-
mulation. Tissue collected from postmor-
tem examinations has been used to define 
cadmium accumulation levels in tissues and 
organs of human subjects (Table 6). In an 
analysis of 61 environmentally exposed sub-
jects between 2 and 89 years of age (mean 
38.5 years), Satarug et al. (2002) revealed that 
renal cadmium accumulation was greater in 
younger age groups with little increase, or 
even a reduction, in the older age groups. 
Some investigators have suggested that 
younger individuals have high rates of renal 
cadmium accumulation because of a very 
high rate of dietary cadmium absorption 
(Horiguchi et al. 2004; Kikuchi et al. 2003). 
Conversely, a lack of renal cadmium accumu-
lation in older individuals may be caused by 
a fall in dietary absorption rate plus a reduc-
tion in tubular reabsorptive capacity, which 
is associated with the aging of the kidney. 
A few studies have examined sex differences 
and cadmium accumulation. For example, 
Satarug et al. (2002) showed that Australian 
women had twice the level of cadmium in 
their livers than did their male counterparts; 
they also noted a trend for higher cadmium 
content in the kidneys of the female subjects. 
Table 6. Cadmium accumulation in the body of 
environmentally exposed subjects.
Study population, 
reference
Cadmium content  
(µg/g wet tissue weight)
Men Women
Australia, Satarug et al. 2002a
Lung 0.11 ± 0.19 0.17 ± 0.35
Liver 0.78 ± 0.71 1.36 ± 0.96b
Kidney cortex 14.6 ± 12.4 18.1 ± 18.0
Japan, Uetani et al. 2006c
Liver 7.9 (2.1) 13.1 (2.1)
Kidney cortex 72.1 (1.7) 83.9 (2.2)
Kidney medulla 18.3 (2.2) 24.5 (2.1)
Pancreas 7.4 (2.0) 10.5 (2.1)
Thyroid 10.6 (2.2) 11.9 (2.0)
Heart 0.3 (1.5) 0.4 (2.0)
Muscle 1.2 (2.1)  2.2 (2.4)
Aorta 1.0 (2.1) 1.1 (1.9)
Bone  0.4 (1.6) 0.6 (1.8)
aAn Australian study comprising 43 men and 18 women, 
2–89 years of age (mean age, 38.5 years). Values are 
arithmetic mean ± SD. bHigher in women than in men. 
cA Japanese study comprising 36 men and 36 women, 
60–91 years of age (mean age, 74 years). Values are geo-
metric mean (SD).Satarug et al.
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Uetani et al. (2006) documented differences 
in cadmium accumulation in a range of tis-
sues and organs between 72 men and women 
who lived in areas with no apparent cad-
mium pollution. In addition, several studies 
on human eyes have shown that the retinal 
pigment epithelium and choroids contained 
more cadmium than did the retina (Erie et al. 
2005; Wills et al. 2008). These studies also 
found that women, men and women of older 
age, and smokers of both sexes had elevated 
levels of cadmium accumulation in eye tis-
sues. Additional studies have demonstrated 
sex differences in ocular metal content in non-
diseased eyes and those afflicted with AMD 
(Wills et al. 2008, 2009). 
Intestinal absorption of metals, body 
burden variability, and metal transporters. 
Highly efficient absorption, transport, and 
cellular uptake mechanisms have evolved in 
living organisms to ensure an optimal sup-
ply of essential metals. Such mechanisms 
are crucial for metals, because they cannot 
be synthesized or destroyed by the cells and 
must be mined from the external environ-
ment (Clemens 2006). As predicted from the 
U-shaped dose–response curve characteristics 
of essential metals, mechanisms designed to 
prevent deficiency or overdose toxicity have 
likely evolved for maintenance of homeo-
stasis (Slikker et al. 2004). Cadmium has no 
known physiologic function, and no mecha-
nism would have been expected to be evolved 
for its selective transport and homeostasis. In 
all likelihood, cadmium is acquired by trans-
port mechanisms developed for essential met-
als. From physical and chemical properties, 
those metals are most likely to be zinc (Zn2+), 
iron (Fe2+), manganese (Mn2+), and calcium 
(Ca2+). In the literature, a considerable range 
defines the possible intestinal absorption rate 
for cadmium. For instance, it was estimated 
to be between 3 and 7% in humans and 
between 0.3 and 3.5% in rats. These values 
were used to assign an average 5% absorption 
rate in deriving a safe exposure level for cad-
mium (IPCS 1992; WHO 1989). However, 
higher cadmium absorption rates (20–40%) 
were shown in balanced studies (Horiguchi 
et al. 2004; Kikuchi et al. 2003). These stud-
ies also observed enhanced rates among young 
subjects and considered the possible biliary 
excretion and reuptake via enterohepatic cir-
culation. Many investigators have shown the 
influence of body iron stores on absorption 
rate and body burden of cadmium. Satarug 
et al. (2004) found a 3- to 4-fold increase in 
cadmium body burden among Thai women 
who had low iron stores when compared with 
those of the same age and of normal iron 
stores. Kippler et al. (2007) found increased 
cadmium burden among Bangladeshi women 
associated with low iron stores only among 
those with adequate zinc status. An inverse 
correlation between serum iron and blood 
cadmium was observed among Canadian 
subjects: men had higher serum iron, blood 
lead, and serum selenium values than did 
women, and women had higher serum cop-
per and blood manganese than did men 
(Clark et al. 2007; Copes et al. 2008). The 
higher blood manganese in women might be 
expected because low iron stores have been 
associated with enhanced manganese absorp-
tion (Finley 1999; Kippler et al. 2009). Some 
studies have shown no influence on body iron 
stores, but these were conducted in chronic 
high-exposure situations where metal trans-
porters would likely be saturated with metal. 
Current data thus suggest metal transporters 
could be one of the determinants of cadmium 
body burden—a factor that may explain the 
variability in blood cadmium levels observed 
by Björkman et al. (2000) in a cohort of 61 
monozygotic and 103 dizygotic twin pairs. 
Conclusions and Perspectives
Recent epidemiologic studies involving an 
exposure–effect assessment have linked low-
level cadmium exposure of current popula-
tions with some adverse effects that are not 
restricted to kidney and bone, but include 
almost every organ and tissue where cad-
mium accumulates, including eye tissues. 
These data argue strongly for public health 
measures aimed at reducing exposure. In the 
past, the wide variation in cadmium body 
burden among people has been attributed 
to cigarette smoking and the high pulmo-
nary absorption rates of cadmium in cigarette 
smoke. However, as revealed in the present 
review, the difference in body burden of cad-
mium between smokers and nonsmokers is 
less than 3-fold. We suggest that the signs of 
early renal injury and mild tubular impair-
ment observed in chronic low-dose exposure 
situations viewed previously as benign could 
indeed be an early warning sign of subclini-
cal or clinical morbidity and mortality. This 
assertion is substantiated by the dose response 
observed between cadmium body burden and 
all-cause mortality and cancer mortality in the 
Belgian and the U.S. cohorts. We also believe 
that cadmium is secreted in breast milk and 
that calcium and zinc supplements could be 
considered to lower the cadmium content in 
breast milk to minimize potential effects of 
early-life exposure to cadmium. 
Many issues require further research. A 
precise risk estimate is needed to quantify 
the carcinogenic risk because the high preva-
lence of cadmium exposure means that even 
a small increase in risk could yield a large 
number of preventable cancer cases. To be 
valid, the threshold-based PTWI model, 
although appearing to be a reasonable method 
for deriving a safe exposure level, will require 
appropriate input from current scientific 
knowledge. Thus, revising the current safe 
intake level for cadmium is much needed. 
A strong consideration should be given to a 
safety factor issue, which is necessary to pro-
tect subpopulations with increased suscep-
tibility, such as those with diabetes. Animal 
studies have shown that the symptoms of dia-
betic nephropathy and cadmium renal toxic-
ity are enhanced when both the metal and the 
disease are present. The enhanced cadmium 
absorption noted for young age groups indi-
cates that new intake guidelines may need to 
be established for pediatric populations. The 
application of the BMD method should be 
expanded and applied to other toxicity end 
points to identify the organs, other than the 
kidney, that should be considered as critical 
for deriving safe exposure levels. The poten-
tial genetically determined rates of cadmium 
absorption, uptake, accumulation, and toxic-
ity remain largely unexplored and should be 
subjects of future research. With the looming 
cancer and chronic disease epidemics world-
wide, we encourage research in the following 
areas: cadmium exposure assessment, iden-
tification of potential exposure sources, and 
the determination of cadmium body burden 
in future epidemiologic investigations. Such 
research would provide an estimate of total 
disease burden (cost) of population exposure. 
In addition, therapeutically effective chelat-
ing agents to enhance excretion of cadmium 
are lacking, and this factor makes preven-
tion of cadmium accumulation pivotal. The 
persistence of cadmium in the environment 
requires a long-term approach to minimize 
human exposure through environmental man-
agement and maintenance of lower cadmium 
levels wherever possible.
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